- Home
- CREV vs CMND Comparison
CREV vs CMND Comparison
Compare CREV & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- CMND
- Stock Information
- Founded
- CREV 2007
- CMND 2017
- Country
- CREV Ireland
- CMND Canada
- Employees
- CREV N/A
- CMND N/A
- Industry
- CREV
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- CMND Health Care
- Exchange
- CREV Nasdaq
- CMND Nasdaq
- Market Cap
- CREV 6.0M
- CMND 5.3M
- IPO Year
- CREV N/A
- CMND N/A
- Fundamental
- Price
- CREV $4.27
- CMND $1.06
- Analyst Decision
- CREV
- CMND
- Analyst Count
- CREV 0
- CMND 0
- Target Price
- CREV N/A
- CMND N/A
- AVG Volume (30 Days)
- CREV 62.3K
- CMND 60.7K
- Earning Date
- CREV 05-14-2025
- CMND 09-15-2025
- Dividend Yield
- CREV N/A
- CMND N/A
- EPS Growth
- CREV N/A
- CMND N/A
- EPS
- CREV N/A
- CMND N/A
- Revenue
- CREV $39,261,077.00
- CMND N/A
- Revenue This Year
- CREV $40.76
- CMND N/A
- Revenue Next Year
- CREV $86.18
- CMND N/A
- P/E Ratio
- CREV N/A
- CMND N/A
- Revenue Growth
- CREV 41.52
- CMND N/A
- 52 Week Low
- CREV $2.00
- CMND $0.80
- 52 Week High
- CREV $12.75
- CMND $2.18
- Technical
- Relative Strength Index (RSI)
- CREV 49.77
- CMND 59.09
- Support Level
- CREV $4.09
- CMND $1.00
- Resistance Level
- CREV $4.66
- CMND $1.05
- Average True Range (ATR)
- CREV 0.36
- CMND 0.05
- MACD
- CREV -0.06
- CMND 0.00
- Stochastic Oscillator
- CREV 24.41
- CMND 79.97
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.